6FN.F

Healthcare Drug Manufacturers - Specialty & Generic

Klaria Pharma Holding AB (publ.)

€0.05

+0.00 +1.69% today

Price History

Not enough data

Key Stats

Market Cap

11.86M

Avg Volume

EPS

-€0.01

52W High

€0.12

52W Low

€0.03

Div. Yield

0.0%

Valuation

P/B Ratio

2.68

Margins

Gross Margin 100.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Assets

(56.8%)

Liquidity & Leverage

Current Ratio

0.20

Quick Ratio

0.20

About

Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction. The company also offers Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. In addition, it is involved in commercialization and sale of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is based in Uppsala, Sweden.